Intra-individual comparison of 18F-sodium fluoride PET–CT and 99mTc bone scintigraphy with SPECT in patients with prostate cancer or breast cancer at high risk for skeletal metastases (MITNEC-A1): a multicentre, phase 3 trial

Results from a study comparing two bone imaging radiopharmaceuticals in detecting bone metastases among patients with high-risk prostate or breast cancer found that ¹⁸F-sodium fluoride (¹⁸F-NaF) PET-CT was more accurate than ^99mTc-methylene diphosphonate (^99mTc-MDP) single-photon emission CT (SPECT; 84.3% [95% CI: 79.9-88.7] vs. 77.4% [95% CI: 72.3-82.5], difference 6.9% [95% CI: 1.3-12.5]; P = 0.016).